Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Trial Profile

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
    • 20 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2020.
    • 21 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top